Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration
2006-001914-34Phase 2Completed
- Sponsor
- Bert Mueller, Dep. Ophthalmology
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in exudative macular degeneration, sponsored by Bert Mueller, Dep. Ophthalmology. Primary endpoint: Loss of more than 15 letters in visual acuity. Started May 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2006-001914-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001914-34.